La catena delle opzioni mostra i dati chiave delle opzioni azionarie di icad a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per icad..

icad (NASDAQ:ICAD) Azioni, Catena delle Opzioni

icad

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

icad Inc

Icade

WIIM

ICAD

Icad shares are trading higher after the company reported better-than-expected Q2 revenue results

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. The company reported quarterly sales of $5.00 million which beat the analyst consensus estimate of $4.42 million by 13.06 percent. This is a 14.75 percent decrease over sales of $5.87 million the same period last year.

Earnings

Earnings Beats

News

icad Q2 2024 GAAP EPS $(0.07), Inline, Sales $5.00M Beat $4.42M Estimate

iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategic agreement with <a href="https://www.globenewswire.com/Tracker?data=jz_5bbVlVgr_KeIBZzBtwJpyyXmLx0ZWLz2yQEtGonvNiCFICN9K_F30xFyl_wvNzq4DKkqfJ_Ste5g6b3SKYw==">Windson</a>g Radiology Group, one of US Radiology Specialists, Inc.'s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to implement iCAD's ProFound AI Breast Health at Windsong Radiology center locations.

Biotech

General

iCAD And Windsong Radiology Ink Strategic Commercial Agreement To Implement AI-Powered Mammography

Events

iCAD to Highlight Research On Potential Of Its AI Algorithm In Breast Cancer Risk Assessment At SIIM 2024

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 87.0% to $0.4 during Monday's after-market session. The company's market cap stands at $6.2 million. </li>
<li>MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) stock increased by 25.94% to $23.35. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares increased by 12.49% to $0.19. The market value of their outstanding shares is at $10.4 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock moved upwards by 11.91% to $0.23. The market value of their outstanding shares is at $2.9 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares moved upwards by 10.75% to $1.75. The market value of their outstanding shares is at $46.4 million. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares moved upwards by 9.3% to $0.46. The market value of their outstanding shares is at $35.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 24.4% to $1.21 during Monday's after-market session. The company's market cap stands at $49.0 million. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 14.04% to $0.84. The company's market cap stands at $14.7 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock decreased by 12.99% to $3.62. The company's market cap stands at $2.1 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares decreased by 9.46% to $1.82. The market value of their outstanding shares is at $15.8 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares declined by 8.86% to $0.17. The company's market cap stands at $3.7 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock decreased by 8.59% to $1.81. The company's market cap stands at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

Alterity Therapeutics Limited - American Depositary Shares

ATHE

DHAI

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

Morgan Stanley Capital Protected Notes for S&P 500 Index

ONCO

RNLX

SCNI

STSS

WORX

12 Health Care Stocks Moving In Monday's After-Market Session

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $4.95 million which beat the analyst consensus estimate of $4.44 million by 11.58 percent. This is a 14.31 percent increase over sales of $4.33 million the same period last year.

icad Q1 Adj $(0.05) Beats $(0.06) Estimate, Sales $4.95M Beat $4.44M Estimate

iCAD And Densitas Partner To Enhance Precision Breast Health With Leading AI Solutions

iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According To New Data Presented At ACC Meeting

iCad shares are trading higher after the company announced a collaboration with Rad-AID to introduce mammography AI-based decision support in LMICs.

iCAD Partners With RAD-AID To Advance Breast Cancer Detection Using AI In Underserved Regions

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
icad beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.
Revenue was down $1.75 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 7.000000000000001% drop in the share price the next day.
Here's a look at icad's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.07</td>
<td>-0.14</td>
<td>-0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>6.27M</td>
<td>5.80M</td>
<td>6.21M</td>
<td>6.68M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>4.07M</td>
<td>5.87M</td>
<td>5.78M</td>
<td>6.49M</td>
</tr>
</tbody>
</table>

To track all earnings releases for icad <a href="https://www.benzinga.com/quote/ICAD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

icad: Q4 Earnings Insights

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $4.741 million which beat the analyst consensus estimate of $4.300 million by 10.26 percent. This is a 26.94 percent decrease over sales of $6.489 million the same period last year.

icad Q4 2023 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $4.741M Beat $4.300M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is likely to report earnings for its fourth quarter.
&bull; MINISO Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $530.30 million.
&bull; BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) is likely to report quarterly loss at $0.91 per share on revenue of $710 thousand.
&bull; Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $45.27 million.
&bull; Tupperware Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUP#NYSE">TUP</a>) is estimated to report earnings for its second quarter.
&bull; Kanzhun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $214.08 million.
&bull; Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) is projected to report quarterly loss at $0.22 per share on revenue of $222.43 million.
&bull; FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $34.53 million.
&bull; Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) is projected to report quarterly earnings at $1.43 per share on revenue of $23.64 billion.
&bull; On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $510.19 million.
&bull; Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $16.09 million.
&bull; Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $-250 thousand.
&bull; Kohl&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is estimated to report quarterly earnings at $1.28 per share on revenue of $5.70 billion.
&bull; PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWFL#NASDAQ">PWFL</a>) is likely to report quarterly loss at $0.10 per share on revenue of $34.34 million.
&bull; Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $197.93 million.
&bull; IHS Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $476.18 million.
&bull; Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $123.96 million.
&bull; Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.24 million.
&bull; Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly loss at $0.10 per share on revenue of $201.84 million.
&bull; Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) is estimated to report earnings for its fourth quarter.
&bull; Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $245.27 million.
&bull; ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) is projected to report earnings for its fourth quarter.
&bull; Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $70.75 million.
&bull; Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) is projected to report quarterly earnings at $0.41 per share on revenue of $1.11 billion.
&bull; Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is projected to report quarterly loss at $0.13 per share on revenue of $48.40 million.
<h3>Companies Reporting After The Bell</h3>
&bull; ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) is projected to report quarterly loss at $0.20 per share on revenue of $6.53 million.
&bull; Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $172.68 million.
&bull; MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $13.09 million.
&bull; Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $111.13 million.
&bull; Performant Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFMT#NASDAQ">PFMT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $31.59 million.
&bull; Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $592.58 million.
&bull; Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is likely to report quarterly loss at $0.08 per share on revenue of $27.00 million.
&bull; Rackspace Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) is projected to report quarterly loss at $0.04 per share on revenue of $714.72 million.
&bull; Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $45.74 million.
&bull; Intl General Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) is likely to report earnings for its fourth quarter.
&bull; Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) is projected to report quarterly loss at $0.15 per share on revenue of $13.48 million.
&bull; Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $0.27 per share on revenue of $1.60 million.
&bull; Surgepays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $33.52 million.
&bull; Maiden Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHLD#NASDAQ">MHLD</a>) is likely to report earnings for its fourth quarter.
&bull; SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) is likely to report earnings for its fourth quarter.
&bull; Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) is projected to report quarterly loss at $2.00 per share on revenue of $2.10 million.
&bull; Doma Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOMA#NYSE">DOMA</a>) is likely to report quarterly loss at $1.30 per share on revenue of $69.42 million.
&bull; Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.07 per share on revenue of $87.63 million.
&bull; Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $8.74 million.
&bull; Aterian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATER#NASDAQ">ATER</a>) is projected to report quarterly loss at $0.13 per share on revenue of $29.34 million.
&bull; Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $4.43 million.
&bull; Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) is expected to report quarterly loss at $0.16 per share on revenue of $30.97 million.
&bull; AdTheorent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTH#NASDAQ">ADTH</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $56.20 million.
&bull; Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.03 per share on revenue of $30.00 million.
&bull; Oportun Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $262.30 million.
&bull; icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is likely to report quarterly loss at $0.05 per share on revenue of $4.30 million.
&bull; Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.18 per share on revenue of $145.56 million.
&bull; Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $73.07 million.
&bull; Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) is likely to report quarterly loss at $1.38 per share on revenue of $1.06 million.
&bull; Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $13.60 million.
&bull; loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $236.76 million.
&bull; CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is estimated to report quarterly loss at $0.29 per share on revenue of $58.40 million.
&bull; Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) is likely to report quarterly loss at $0.10 per share on revenue of $42.84 million.
&bull; Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $480.25 million.
&bull; Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $226.02 million.
&bull; Eastern Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EML#NASDAQ">EML</a>) is likely to report earnings for its fourth quarter.
&bull; BRT Apartments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRT#NYSE">BRT</a>) is estimated to report earnings for its fourth quarter.
&bull; Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is expected to report quarterly loss at $0.06 per share on revenue of $87.21 million.
&bull; Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is likely to report quarterly loss at $0.11 per share on revenue of $151.50 million.
&bull; Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) is projected to report quarterly loss at $0.23 per share on revenue of $69.06 million.
&bull; Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $47.25 million.
&bull; PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $9.37 million.
&bull; Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is likely to report quarterly loss at $0.15 per share on revenue of $33.79 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADTH

ALGS

ATER

AWRE

BIRD

BLDE

BTAI

BTMD

CLOV

CLPT

CLSD

CRMD

CSBR

CYRX

DOMA

ENFN

GHLD

HGTY

HRTX

IGIC

INVE

LCUT

MANU

MHLD

MNSO

MXCT

NATR

NOTE

NRGV

ONON

OPRT

PFMT

PHUN

PRPL

PRTH

PWFL

QFIN

QRHC

REFI

RERE

SIGA

SKIN

SNCR

SURG

SWIM

TACT

TNON

VERI

WEST

WKHS

Earnings Scheduled For March 12, 2024

icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Here's what investors need to know before the announcement.
Analysts estimate that icad will report an earnings per share (EPS) of $-0.05. 
icad bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 6.99% drop in the share price the next day.
Here's a look at icad's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.14</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.07</td>
<td>-0.14</td>
<td>-0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
<td>-9.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710176458_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of icad were trading at $1.89 as of March 08. Over the last 52-week period, shares are up 30.07%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/ICAD/earnings">To track all earnings releases for icad visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For icad

iCAD shares are trading higher after the company announced that it will highlight a new release for its AI-powered ProFound Detection solution.

<ul>
<li>Clinical evidence demonstrates ProFound Detection's AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives</li>
<li>Findings reveal substantially lower radiology reading workload</li>
<li>Detection of Breast Arterial Calcification (BAC) by ProFound Heart Health could serve as biomarker to evaluate broader cardiovascular disease in women &nbsp;</li>
</ul>
NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, Feb 28 – March 3, 2024. The Company also announced it will highlight a new release for its AI-powered ProFound Detection solution while showcasing its full Breast Health Suite in booth X1 AI-35.
"The data presented at ECR demonstrate the real-world ability to improve efficiency and accuracy in mammography breast screening—from reducing workloads without compromising accuracy to potentially reducing interval cancer rates and expediting diagnosis for true positive cases. These findings underscore ProFound AI's transformative power to improve breast healthcare," said Dana Brown, president and CEO of iCAD.
"Furthermore, we are thrilled to showcase new workstation features to improve the readability of iCAD's primary solution, ProFound Detection," continued Brown. "This includes limiting lesion marks to the three highest-scoring lesions, which may be color-coded based on lesion score. Additionally, the ProFound Scorecard may be color-coded based on case score categories, with options for score range fine-tuning based on a facility's real-world data. For radiologists, these latest enhancements further improve and facilitate their reading of mammograms."
New Research The following three oral and award-winning poster presentations highlight the clinical research being presented at ECR 2024. Detailed information may be found <a href="https://www.globenewswire.com/Tracker?data=DiHaNQV8biwSR7wyyeruhkFAiTaN1f7bzPeJo0JHzUZVAI8dhd4M3aOU8_9laUGZ8A54lv-vvs0cMsBdmMnHdNPjA68Z1z3GYrhe22pUjQA=">here</a>.
<ul>
<li>Friday, March 1, 8:00 – 9:00 am, RPS1202 – Adding Artificial Intelligence (AI) Case Malignancy Scoring in a Breast Screening Program to Reduce Screen-Reading Workload: A Retrospective Study. The study conducted by A. Nitrosi et al. at the Reggio Emilia Breast Screening Program in Italy aimed to assess the integration of iCAD's artificial intelligence mammography case malignancy scoring (AI-CMS) into a breast screening program to alleviate screen-reading workload without compromising accuracy. Analyzing data from 31,747 screening exams, including 92 proven tumors, the study simulated two integrated AI and human reading protocols (ProFound AI 2D system). Results showed that implementing ProFound AI-CMS could substantially reduce the number of human readings and workload by 24.8% to 30.6%, with a modest improvement in recall rate and no increase in false negatives observed with 10% and 15% Case Score thresholds. &nbsp;</li>
<li>Sunday, March 3, 9:30&nbsp;–&nbsp;11:00 am, RPS2305 – Retrospective Evaluation of Interval Breast Cancer: Can the Number of Interval Carcinomas be Reduced Utilizing AI Diagnostic Software? In this study conducted by Jonas Subelack et al., researchers from the University of St. Gallen and Krebsliga Ostschweiz in Switzerland and Radiologie am Theater in Germany assessed whether iCAD's ProFound AI could help reduce interval carcinomas (ICs). Analyzing data from 151,245 screening mammograms between 2010 and 2019, the study identified 264 ICs where cancer was detected within 24 months after screening that was considered normal. Expected results anticipate improved IC detection rates with the software compared to initial screening, with detection accuracy influenced by set thresholds. The study expects the software to outperform radiologists in IC detection, suggesting potential integration into mammography screening to reduce ICs. &nbsp;</li>
<li>Sunday, March 3, 11:30 am – 12:30 pm - RPS 2405 – Adding Artificial Intelligence (AI) Case Malignancy Scoring in a Breast Screening Program to Overcome Delay in Most Probably True Positive Cases: A Retrospective Study. The retrospective study at the Reggio Emilia Breast Screening Program in Italy led by A. Nitrosi et al. aimed to assess the efficacy of implementing iCAD's ProFound AI case scoring strategy in a breast screening program to expedite the reading process for potentially true positive cases, ensuring compliance with local regulations requiring readings within two weeks. Analyzing data from 32,012 2D mammography screening exams, the study utilized the ProFound AI 2D system. The AI-generated Case Scores, representing the algorithm's confidence in malignancy, were used to prioritize readings. Results showed that reading screening exams above certain Case Score thresholds identified 61% to 89% of screen-detected cancers while requiring only 5.4% to 20% of screening exams to be read. Notably, prioritizing readings of exams with Case Scores above 40% allowed for the recall of the majority (85%) of true positive cases within a short time frame. &nbsp;</li>
<li>ECR 2024 Awarded - <a href="https://www.myesr.org/congress/awards/">Certificate of Merit</a> E-Poster Presentation – Breast Arterial Calcification (BAC): A Proxy for Medium and Large Vessel Atherosclerotic Calcium. In this retrospective study by C. Parghi et al., researchers investigated the correlation between breast arterial calcification (BAC) as detected by ProFound AI Heart Health on screening mammograms from Solis Mammography and the extent of atherosclerotic disease observed on CT imaging within 12 months of the mammogram. Analyzing data from 1,449 women, they found that a BAC score of 3 or more was associated with a significantly higher rate of clinically significant atherosclerotic disease in large and medium vessels compared to a BAC score of less than 3. Specifically, the rate increased from 11.0% to 31.0% (p &lt; 0.001). The sensitivity, specificity, and accuracy for detecting clinically significant atherosclerotic disease when the BAC score was 3 or more were 21.8%, 92.9%, and 83.8% respectively. These findings suggest that quantitative BAC assessment could offer insight and potentially identify those who need further cardiovascular screening. &nbsp;</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=fXgRfKpAODHFkZGxvn1Uc8soKi5NPO5CeMwMPF0mGAmgr8fyEnFSLAvUThPZx1lwiewKkwG79ekgw89o9vLXoPDP1jKHakEf2A7ArfUWTCfIC09DHqUtbSuRRYlv-i3I">Chirag Parghi</a>, M.D., chief medical officer of Solis Mammography and a pioneer in the use of mammography to assess BAC, won the <a href="https://www.globenewswire.com/Tracker?data=avMRKUn4daBjaWlZoNInvEG3n0DpB5Ehkpe7tprOz_JGER9VKkv8ORQ8bGtExWXT9LlYinq4AVVpsNm92X1s6QP92Eh76N6ubkZI5XCctriFhiPrpDelCoilG6eSC7fL">Certificate of Merit</a> award for this poster presentation. "I am encouraged by our findings, which highlight the potential of Breast Arterial Calcification (BAC) assessment in revolutionizing access to cardiovascular risk assessment. Our research demonstrates the significance of a quantitative BAC score indicating a higher likelihood of clinically significant atherosclerotic disease elsewhere in the body, identifying individuals who may benefit from further cardiovascular screening. These results continue to advocate for screening mammography as a portal to screen for both breast cancer and cardiovascular risk, the top two causes of death in women worldwide."
Enhancements for ProFound Detection for 2D and 3D Mammography The new workstation features included in the updates to ProFound Detection's Third Generation solution were designed to improve readability of iCAD results through a configuration option to limit to three lesion marks visible on a 3D view. This refinement ensures that radiologists can interpret the most critical information without multiple markings, streamlining the diagnostic process for more efficient decision-making.
Moreover, the introduction of color-coded lesion marks and case score on the ProFound Scorecard provides an intuitive visual aid, allowing radiologists to discern the suspicion level of detected abnormalities quickly. This color-coded system, based on cancer occurrence per screening population, offers a concise, comprehensive representation of the severity of detected lesions and the overall case, further facilitating accurate diagnosis and prioritization of cases.
Additionally, support for the ability to fine-tune score ranges based on real-world data enables users to customize the detection system according to their specific clinical needs, supporting performance and adaptability to varying patient populations.
Lastly, iCAD will highlight expanded cloud platform and subscription licensing plans marking a significant advancement in deployment flexibility. iCAD's new Success Program offers a full range of ongoing software updates to ensure customers have the latest version of iCAD's AI offerings, system maintenance, and customer support.
To discover more about iCAD's presence at the ECR 2024 annual meeting or to schedule time with the iCAD team, virtually or in-person, visit <a href="https://www.globenewswire.com/Tracker?data=PLiuiNsEhXoAvln-joXvH6bUPeaJgTSai1gV-HSVKAG7nF0L72Z4ef5TFyYhKSd7UHG9SOYWuUrOBwBM9zLy7URKrRs4dkZFew1vpr9vCD4=">www.icadmed.com/ecr-2024</a>

iCAD Highlights Clinical Data Demonstrating Ability To Reduce Breast Interval Cancer Rates And Decrease Recall Rates At ECR 2024; Showcases Additional Platform Offerings

iCAD shares are trading higher after the company announced that AI-powered solutions from its ProFound Breast Health Suite are integrated into GE HealthCare's new offering.

GEHC

iCAD Announces Apps From The iCAD Breast Health Suite Are Now Integrated Into GE HealthCare's MyBreastAI Suite

<h3>Gainers</h3>
<ul>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares rose 38.1% to $8.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $630.6 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares moved upwards by 22.98% to $0.26. The market value of their outstanding shares is at $12.8 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares moved upwards by 17.99% to $1.18. The company's market cap stands at $13.0 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares increased by 17.51% to $1.61. The market value of their outstanding shares is at $42.4 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock moved upwards by 10.81% to $0.25. The market value of their outstanding shares is at $4.5 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares increased by 10.78% to $0.34. The company's market cap stands at $15.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 69.5% to $1.07 during Tuesday's pre-market session. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock decreased by 38.3% to $1.16. </li>
<li>CohBar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWBR#NASDAQ">CWBR</a>) shares fell 23.91% to $0.68. The company's market cap stands at $1.9 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares declined by 13.67% to $0.29. The market value of their outstanding shares is at $2.1 million. </li>
<li>Better Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTTX#NASDAQ">BTTX</a>) stock decreased by 12.51% to $0.17. The market value of their outstanding shares is at $8.0 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) stock decreased by 10.48% to $0.2. The market value of their outstanding shares is at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTTX

CWBR

CYTO

EIGR

HSCS

RDHL

SNES

THAR

VRAX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<ul>
<li>New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman's one to two-year risk for breast cancer &nbsp;</li>
<li>iCAD unveils new solution that assesses calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women in the U.S.</li>
<li>Dr. Emily Conant, Perelman School of Medicine, University of Pennsylvania, to present how iCAD's 4th generation Breast AI is harnessing innovations to improve patient outcomes &nbsp;</li>
</ul>
NASHUA, N.H., Nov. 27, 2023 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gry5_t-atqlYoQWtVUxThMFu3MTsZVS_Z2h08k8ROyoLMRuxpRLJ84FxyWmbqB0hwqRxjeFxkEW03gLZXkxWYg==">iCAD, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>), a global medical technology leader in innovative cancer-detection solutions, will present new studies validating its artificial intelligence (AI) powered <a href="https://www.globenewswire.com/Tracker?data=c6iRlYl2xPAvwVULWiSZ_YT1evN0nA_8gyG5typAbw06cBw-LJfd759Mfl2Mp2bIDAJkLeTJxMsvt_EwYVNAHgNs2yMOOjuA4f4i-eqrBPAWhYAs5-9p_pOKLZd5cdg1Sf4KMImkf1heJu9BNmNszA==">ProFound Breast Health Suite</a> for uncovering hidden heart or vascular disease and predicting a woman's risk for developing breast cancer in the next one- or two-years. Researchers will present their findings at the Radiological Society of North America's (<a href="https://www.globenewswire.com/Tracker?data=-O6rSBBA1e9IKca1UTWlhPFF3Ctuth0JWEqS99L-T987mTEPb68Dr1Iy71shX1ywUjsp_-OMrauSh7bIXyE-_A==">RSNA</a>) annual meeting in Chicago, Nov. 27 – 30, 2023.
Blending artificial intelligence with computer-aided detection (AI CAD), the iCAD software platform, ProFound Breast Health Suite, can screen a single mammogram for two of the top causes of death for women: breast cancer and heart disease. ProFound AI improves accuracy, streamlines clinical workflow and delivers results to patients more quickly.
"The ProFound Breast Health Suite significantly increases cancer detection rates with up to 2x enhanced clinical performance compared to other AI platforms, and reduces the rate of false positive results while accurately evaluating a woman's breast density and cancer risk," said Dana Brown, president and CEO of iCAD, Inc. "Our growing body of important research illustrates the potential our newest solution, ProFound Heart Health, holds for the assessment of calcium deposits in the breast arteries as a proxy for hidden cardiovascular disease, the leading cause of death for women worldwide. We believe iCAD's ProFound AI has the power to positively transform healthcare for clinicians and patients alike."
Catching cardiovascular disease through mammography
Recent research shows that calcium deposits inside the blood vessels of the breast correlate to hardening of the cardiovascular arteries. In fact, women with breast arterial calcifications, or BAC, are <a href="https://www.globenewswire.com/Tracker?data=7EKH1r77Q3U_Vka6KSKil4wJngVQc8WeqeTAWf41iKTHh1rYjoakdOFsEpvDUcZV7lMqmREwURYjhW3F_445EM2xfwLgktCVQB-oAKyBd0q6AwWGeqYOgVBJrR-bBQxfDdegw4cynfzqYmclwR71fgX1m28mz37kWLzmRbyDe0dQKssibbAY6_sEyTQXSzTS">51% more likely</a> to develop heart disease. iCAD's report on the existence of arterial calcification, along with easy-to-understand visual representations that demonstrate the extent of calcification, can help women work with their physicians to further evaluate their cardiovascular health and identify any potential need for intervention.
<a href="https://www.globenewswire.com/Tracker?data=sSiVjKUKSsL5P6jrX5mJ7FqjfqFYiJWDqXSU0rYWR3KnRnac8Foow0Wad9yVgO-0An2nE8XbJN0dmNXr3WU4wlP7lH4eE86C8I6gmD83q3z_t8pxYyCY7gsgQiYrkiTe">Chirag Parghi</a>, M.D., chief medical officer of <a href="https://www.globenewswire.com/Tracker?data=Dc8BuY4iMIdwIlP6CMnUbymVSzvAnbOA5D3PSCvnxqi43FipGBg5dQ-6SpAMp9vBfTBf8Ydz_XH1_hck9kRXKSEd3UI4tc47ETdH3CSDyGc=">Solis Mammography</a>, and a pioneer in the use of mammography to assess BAC, will present his team's findings from a 15-site prospective study that reviewed 2D screening mammograms from 15,785 asymptomatic women, ages 20 to 97. He and his colleagues found the ProFound Heart Health AI algorithm highly accurate in uncovering BAC in mammograms. The calcium deposits appeared more common and widespread with age, as expected.
"Radiologists currently rely on visual detection of breast arterial calcifications, which is time-consuming and leads to a national underreporting of BAC results in mammography reports," explained Dr. Parghi. "Our study suggests that AI can standardize BAC detection on a large scale, speeding up the measurement process and reducing variations between reviewers. By standardizing BAC reporting, AI increases the ease of identifying women that may benefit from additional cardiovascular screening." Dr. Parghi's oral presentation will occur on Tuesday, Nov. 28, 9:30 - 10:30 am CST: "AI Assessment of Breast Arterial Calcifications on Mammography in a Large Screening Population" (Session T3-SSBR05).
Accurately predicting personal breast cancer risk <a href="https://www.globenewswire.com/Tracker?data=tW21NybxFv2QoZddFgDq6ruWqvFr2S8tGlnlXlBTMeD8gM2qu0Pxs7owX5N6lQsTAu3DL8qXls6Duy2uSSmNJKBgO2VbbZRPLz7MuvmIjML-jaR4Idrg3MsOBA8FmGLX">Axel Gräwingholt</a>, M.D., head of mammography screening at <a href="https://www.globenewswire.com/Tracker?data=G0IaJ6yxnrXwqaqjsA9Rr1tmR34uJUTcCsArugcsNG5BPhvtvb-NO4PX0xWsZzGBlJHKAJ_na3OR7Avyw-Exo4G-8z8mjcfgIYBHXqIEBAn8LZb0Cgq5wGPt8x-7Ho3x">Radiologie am Theater</a> in Germany, will present his team's findings from a retrospective study of ProFound Risk for 2D Mammography. He and his colleagues assessed ProFound Risk's effectiveness in identifying women at high risk for developing breast cancer in the next two years based on microscopic changes on their exams.
The researchers used ProFound Risk to screen the mammograms of 53,453 women who had received normal results two years earlier from their radiologists. The program flagged 42.8% of the women, or 22,878 patients, at a higher risk for breast cancer.
ProFound Risk's prediction proved correct. The average risk for women in the study who developed breast cancer two years after their mammogram was 2.4 times higher than for those who remained cancer-free. The average risk for invasive cancers exceeded that of ductal carcinoma in situ (DCIS), a slow-growing cancer of the milk ducts.
"Our findings suggest AI enables radiologists to identify women who would benefit from more frequent screenings, or suggest supplemental screenings, without leading to overdiagnosis," said Dr. Gräwingholt. "ProFound Risk accurately pinpoints women at high risk for breast cancer while helping us discover small, subtle and aggressive cancers that often go undetected by the naked eye. We believe this technology could greatly enhance the effectiveness of breast cancer screening strategies worldwide."
Dr. Gräwingholt's oral presentation will occur on Monday, Nov. 27, 8:00 – 9:00 am CST: "Real-World Use of AI Risk Scores to Identify Women at High Risk for Breast Cancers with Sub-analyses Based on Histopathology and Time of Detection" (Session M1-SSBR03).
Other presentations of note:
<ul>
<li><a href="https://www.pennmedicine.org/providers/profile/emily-conant">Emily Conant, M.D.</a>, professor of Radiology and Vice Chair of Faculty Development in the Department of Radiology at the University of Pennsylvania, Perelman School of Medicine, will deliver an Industry Summit presentation, "From Pixels to Practice: Harnessing Innovations in Breast AI to Improve Patient Outcomes." showcasing promising early testing results from iCAD's newest 4th generation AI for breast cancer detection Monday, Nov. 27, 3:30 – 3:45 pm CST (AI Showcase Theater)</li>
<li>Thu Ha Dao, M.D., a radiologist at Hôpitaux Universitaires Henri Mondor in France, will deliver a poster presentation on Sunday, Nov. 26 from 12:15 – 12:45 pm CST: "Evaluation of a Deep-learning based Software Tool to Automatically Detect and Quantify Breast Arterial Calcifications in Digital Mammograms." (Session S3B-SPBR-1)</li>
<li><a href="https://staff.ki.se/people/mikael-eriksson">Mikael Eriksson</a>, Ph.D., a postdoctoral researcher of medical epidemiology and biostatistics at the Karolinska Institute in Sweden, will deliver a poster presentation on Monday, Nov. 27 from 12:45 – 1:15 pm CST: "Multi-national validation of a clinical image-based AI-risk model for individualizing breast cancer screening." (Session M5B-SPBR-4)</li>
<li>iCAD staff will showcase the ProFound Breast Health Suite in an interactive exhibit for attendees demonstrating how to add and scale AI in their radiology practices. (RSNA South Hall, Booth 3940). Solutions demonstrated include:
<ul>
<li>ProFound Detection&#x2A;: both the current cleared breast cancer detection 3.0 version and future 4.0 version (4.0 not yet FDA cleared) will be available to observe for their ability to detect tumors; as well as the newest 2D version developed in collaboration with Google Health (not yet FDA cleared or CE marked).</li>
<li>ProFound Density: a solution for objective, standardized assessments of breast density.</li>
<li>ProFound Risk&#x2A;&#x2A;: predicting a woman's one- and two-year risk for developing breast cancer.</li>
<li>ProFound Heart Health&#x2A;&#x2A;&#x2A;: a new solution for measuring cardiovascular calcium deposits, alerting to possible vascular or heart disease (pending FDA clearance).</li>
</ul>
</li>
</ul>
iCAD will also host a series of "Meet the Experts" sessions throughout the annual meeting featuring radiology, research, and technology leaders in breast imaging AI who will be available to share their experience with the ProFound Breast Health Suite. To learn more about iCAD's presence at RSNA or to RSVP for an event, please visit <a href="https://www.globenewswire.com/Tracker?data=d7hV1B9LL1t-s6Z1dkb3JuqWAzPcuSetFlR11Dk00GGkjOuKqYgtFSTUpnCoQCqoy47VSdOfw13ZuP3_9u5WZwl9PKRGIMNvA0KgeL7FpUywFdL-GOZ38Q7BYHesKiiQusZ6Tj2yin5w2URqYvmMUA==">https://web.icadmed.com/RSNA-2023.html</a>
&#x2A;ProFound Detection version 4.0 and ProFound Detection for 2D in partnership with Google are not yet submitted for FDA clearance or available for sale in the U.S. or CE Marked. &#x2A;&#x2A;ProFound Risk is CE Marked, Health Canada Licensed, and available for investigational use only in the U.S. &#x2A;&#x2A;&#x2A;ProFound Heart Heath is available for investigational use only, pending regulatory approval in the U.S. and Europe.

iCAD's ProFound AI Can Predict 1-2 Year Risk For Breast Cancer And Reveal Insights For Heart Disease

In a report released today, Per Ostlund from Craig-Hallum maintained a Buy rating on iCAD (ICAD – Research Report). The company's shares closed yes...

Craig-Hallum Keeps Their Buy Rating on iCAD (ICAD)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
icad (NASDAQ:<a href="https://investorplace.com/stock-quotes/icad-stock-quote/">ICAD</a>) just reported results for the first quarter of 2024.<ul><li>icad reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -6 cents.</li><li>The company reported revenue of $4.95 million.</li><li>This was 11.58% better than the analyst estimate for revenue of $4.44 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/icad-stock-earnings-icad-for-q1-of-2024/">ICAD Stock Earnings: icad Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICAD Stock Earnings: icad Beats EPS, Beats Revenue for Q1 2024

iCAD, Inc. (ICAD) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s certainly a very good time to be in the AI business. After all, the technology has been getting huge amounts of positive publicity since December 2022, and it&rsquo;s being viewed as a powerful, helpful tool for humans. As a result, many <a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a>, such as Palantir (NYSE:<a href="https://investorplace.com/stock-quotes/pltr-stock-quote/">PLTR</a>), SoundhoundAI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) and Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>), have skyrocketed. But there are still a multitude of small-cap AI stocks that are laboring in obscurity. These firms have all the advantages of being involved in AI, but their stocks do not yet come close to reflecting their tremendous potential. Here are three small-cap <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to buy.



<h2>Innodata (INOD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/artificial-intelligence-purple-ai-symbol-1600-300x169.jpg" alt='AI stocks to buy now, Graphic of letters "AI" in bold font surrounded by circle of tech symbols in purple and blue against a dark background. ai stocks to buy'><div>Source: shutterstock.com/Tex vector</div></div>Innodata (NASDAQ:<a href="https://investorplace.com/stock-quotes/inod-stock-quote/">INOD</a>) <a href="https://seekingalpha.com/article/4683237-innodata-stay-away-from-this-ai-stock">uses data sets to train</a> AI models for other firms. Innodata also helps businesses direct their AI models to perform certain tasks. Additionally, the firm <a href="https://finance.yahoo.com/quote/INOD/profile">digitalizes medical</a> records and provides a marketing platform.



Many large companies, including IBM (NYSE:<a href="https://investorplace.com/stock-quotes/ibm-stock-quote/">IBM</a>), Palantir and Accenture (NYSE:<a href="https://investorplace.com/stock-quotes/acn-stock-quote/">ACN</a>), are helping firms implement AI. But my sense is that Innodata is more technical and enables more detailed capabilities than many of these firms. Moreover, Innodata, which was founded back in 1988, is largely dedicated to AI and likely has much more experience with the technology than many if not most of its competitors.



Last quarter, the firm&rsquo;s top line <a href="https://seekingalpha.com/pr/19716203-innodata-reports-record-first-quarter-2024-results-raises-guidance-to-least-40-percent?hasComeFromMpArticle=false">jumped 41% versus</a> the same period a year earlier to $26.5 million. Its EBITDA, excluding certain items, came in at $3.8 million, up from $800,000 in Q1 of 2023. 



Investor&rsquo;s Business Daily gives INOD stock an Accumulation/Distribution grade of B. That&rsquo;s a high grade for a small-cap stock and indicates that many institutional investors are starting to buy INOD stock.



Given the firm&rsquo;s strong outlook and powerful growth, along with the Street&rsquo;s interest in the name, INOD stock is one of the top small-cap growth stocks to buy.



<h2>Mitek Systems (MITK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/04/identity-managment-300x169.jpg" alt="A concept image of a person touching a hologram fingerprint"><div>Source: Alexander Supertramp/Shutterstock.com</div></div>Mitek Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/mitk-stock-quote/">MITK</a>) <a href="https://www.miteksystems.com/technology">provides identity software</a> that utilizes AI. Currently, its technology is used to enable consumers to deposit checks with their smartphones and to detect check fraud. However, given increases in online fraud and continuous advances in AI, along with increased interest in the technology, I expect Mitek to use its technology to introduce new, highly successful products over the longer term. Indeed, the firm has developed voice authentication technology <a href="https://seekingalpha.com/article/4692924-mitek-systems-inc-mitk-q2-2024-earnings-call-transcript">that it says </a>&ldquo;opens up several new avenues for growth.&nbsp;&ldquo;



During Mitek&rsquo;s FY that ended in September 2023, its revenue<a href="https://seekingalpha.com/symbol/MITK/income-statement"> came in at </a>$172.6 million, up from $144.8 million during the previous fiscal year. Additionally, it generated operating income of $21.1 million. up from $15.7 million during the previous year.



Mitek <a href="https://finance.yahoo.com/quote/MITK/key-statistics">has a low forward price-</a>earnings ratio of 14.4 times.



<h2>iCAD (ICAD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>iCAD&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/icad-stock-quote/">ICAD</a>) products utilize AI to more accurately detect breast cancer. Last quarter, the company&rsquo;s sales team<a href="https://seekingalpha.com/article/4693537-icad-inc-icad-q1-2024-earnings-call-transcript"> began systematically </a>using lead generation programs for the first time and added four new sales representatives to its team which had previously utilized six sales representatives. Additionally, in December, the firm added a new head of North American sales in December. Finally, iCAD worked harder to obtain more revenue from its existing customers.



The changes enabled iCAD to grow very rapid as its revenue climbed 14% last quarter versus the same period earlier to $4.95 million. Making the gain even more impressive, iCAD had <a href="https://www.nsmedicaldevices.com/news/us-based-icad-to-divest-brachytherapy-subsidiary-xoft-to-elekta/">divested its cancer therapy business</a>, Xoft, at the end of last year.



Also impressively, the firm made significant, new deals last quarter with entities in Turkey, Israel, Serbia and France in Q1. These contracts indicate that the company can generate meaningful revenue going forward from countries outside of North America.



I believe that iCAD&rsquo;s current <a href="https://finance.yahoo.com/quote/ICAD">market capitalization</a> of $43 million is many times below its long-term potential.



On the date of publication, Larry Ramer held a long position in ICAD. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.&nbsp; &nbsp; &nbsp;
<div>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel&rsquo;s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/3-top-small-cap-growth-opportunities-in-the-ai-era/">3 Top Small-Cap Growth Opportunities in the AI Era</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Top Small-Cap Growth Opportunities in the AI Era

Nvidia Stock: It's Time To Take Profits

iCAD (ICAD) has issued an announcement. At iCAD, Inc.'s 2024 annual stockholders' meeting, a quorum of over 19 million shares voted on key proposal...

iCAD Stockholders Elect Directors, Approve Incentive Plan

Craig-Hallum Sticks to Their Buy Rating for iCAD (ICAD)

iCAD Non-GAAP EPS of -$0.07 in-line, revenue of $5M beats by $0.57M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
icad (NASDAQ:<a href="https://investorplace.com/stock-quotes/icad-stock-quote/">ICAD</a>) just reported results for the second quarter of 2024.<ul><li>icad reported earnings per share of -7 cents. This met the analyst estimate for EPS of -7 cents.</li><li>The company reported revenue of $5.03 million.</li><li>This was 13.78% better than the analyst estimate for revenue of $4.42 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/icad-stock-earnings-icad-for-q2-of-2024/">ICAD Stock Earnings: icad Meets EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ICAD Stock Earnings: icad Meets EPS, Beats Revenue for Q2 2024

iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript

AAPL

CSCO

GOOG

GOOGL

INOD

LMND

MITK

MSFT

NVDA

PLTR

SMCI

SOUN

Press Releases

iCAD Reports Financial Results for First Quarter Ended March 31, 2024

Health Care

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024

iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography

iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024

iCAD Reports Financial Results for Second Quarter Ended June 30, 2024

iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

Comments

icad

icad (ICAD) Opzioni

icad (NASDAQ:ICAD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO